Nitta Daisuke, Kinugawa Koichiro, Imamura Teruhiko, Endo Miyoko, Inaba Toshiro, Maki Hisataka, Amiya Eisuke, Hatano Masaru, Kinoshita Osamu, Nawata Kan, Kyo Shunei, Ono Minoru
Department of Cardiovascular Medicine, Graduate School of Medicine, The University of Tokyo.
Circ J. 2016;80(2):387-94. doi: 10.1253/circj.CJ-15-1030. Epub 2015 Dec 4.
Although destination therapy (DT) is now expected to be a promising strategy for those who are not suitable for heart transplantation in Japan, there has not been any investigation into ineligibility for bridging to implantable left ventricular assist device (I-LVAD) as DT among patients with extracorporeal LVAD.
We retrospectively studied 85 patients who had received an extracorporeal LVAD. To assess ineligibility for a bridge to I-LVAD for DT, we defined DT ineligibility (DTI) as BiVAD requirement, death within 6 months, and persistent end-organ dysfunction (medium or high J-VAD risk score) at 6 months after extracorporeal LVAD implantation. DTI was recorded for 32 patients. Uni/multivariate analysis showed that smaller left ventricular diastolic dimension (<64 mm; [odds ratio (OR) 4.522]), continuous hemodiafiltration (OR 4.862), past history of cardiac surgery (OR 6.522), and low serum albumin level (<3.1 g/dl; OR 10.064) were significant predictors of DTI. By scoring 2, 2, 3, 4 points, respectively, considering each OR, we constructed a novel scoring system for DTI (DTI score), which stratified patients into 3 risk strata: low (0-3 points), medium (4-6 points), and high (7-11 points), from the view point of DTI risk (low 8%, medium 46%, high 93%, respectively).
DTI score is a promising tool for predicting ineligibility for I-LVAD as DT before extracorporeal VAD implantation.
尽管在日本,对于那些不适合心脏移植的患者,目标治疗(DT)目前被认为是一种有前景的策略,但尚未有关于体外左心室辅助装置(LVAD)患者中作为DT过渡到植入式左心室辅助装置(I-LVAD)的不适合性的研究。
我们回顾性研究了85例接受体外LVAD治疗的患者。为评估作为DT过渡到I-LVAD的不适合性,我们将DT不适合性(DTI)定义为双心室辅助装置(BiVAD)需求、6个月内死亡以及体外LVAD植入后6个月持续存在的终末器官功能障碍(中度或高度J-VAD风险评分)。32例患者记录了DTI。单因素/多因素分析显示,较小的左心室舒张内径(<64 mm;[比值比(OR)4.522])、连续性血液透析滤过(OR 4.862)、心脏手术史(OR 6.522)以及低血清白蛋白水平(<3.1 g/dl;OR 10.064)是DTI的显著预测因素。通过分别考虑每个OR给予2、2、3、4分,我们构建了一种新的DTI评分系统(DTI评分),从DTI风险角度将患者分为3个风险分层:低(0 - 3分)、中(4 - 6分)、高(7 - 11分)(分别为低8%、中46%、高93%)。
DTI评分是预测体外VAD植入前作为DT使用I-LVAD不适合性的一种有前景的工具。